Cumulus Neuroscience annonce la publication d'un article dans Scientific Reports démontrant que la plateforme NeuLogiq® est viable et utilisable pour l'évaluation cognitive multimodale à domicile chez les personnes atteintes de sclérose latérale amyotrophique (SLA) et de dégénérescence fronto-temporale (DFT)

Data ReadoutpositiveNeuLogiq®Positive

AI Analysis

Summary

Cumulus Neuroscience published results from study CNS-102 in Scientific Reports demonstrating that its NeuLogiq® platform is viable for remote multimodal cognitive assessment in ALS and frontotemporal dementia patients, with 82% of ALS participants rating it acceptable.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Study CNS-102 results published in Scientific Reports showing NeuLogiq® platform is viable and usable for multimodal cognitive evaluation at home in ALS and FTD patients; 82% of ALS participants found the platform acceptable

Importance:5/10

Sentiment:

0.70

neurosciencedigital healthALSFTDclinical trialhome-based testingpublication

Read the original article

Published by PR Newswire Pharma on August 20, 2026 10:45 AM

Read Original